香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 GIANT BIOGENE HOLDING CO., LTD 巨子生物控股有限公司 （於 開 曼 群 島 註 冊 成 立 的 獲 豁 免 有 限 公 司） （股 份 代 號：2367） 本 公 司 欣 然 宣 布，本 公 司 全 資 子 公 司 陝 西 巨 子 生 物 技 術 有 限 公 司 於 今 日 收 到 中國國家藥品監督管理局頒發的關於重組I型α1亞型膠原蛋白及透明質酸鈉 複合溶液產品（「本產品」）的《中 華 人 民 共 和 國 醫 療 器 械 註 冊 證》（註 冊 證 編 號：國 械註准20263130044）。本 產 品 以 重 組 膠 原 蛋 白 及 透 明 質 酸 鈉 為 主 要 成 分，用 於 真 皮 層 的 注 射，以 改 善 面 頰 部 平 滑 度。 本產品是全球首個用於改善面頰部平滑度的重組膠原蛋白和透明質酸鈉複合 溶 液 ...

Core Viewpoint - The company is optimistic about the recombinant collagen market, highlighting its advantages in safety, efficacy, and sustainability, which are seen as fundamental drivers for industry development [1] Group 1: Industry Insights - Recombinant collagen production occurs in controlled fermentation environments, mitigating risks associated with animal-derived collagen, such as viral transmission and allergic reactions [1] - The technology allows for precise production of recombinant collagen with specific amino acid sequences, enhancing targeted efficacy for various applications, including anti-wrinkle and tissue regeneration [1] - The fermentation process offers scalability and consistency, enabling low-cost, high-quality production, thus overcoming limitations faced by animal-derived collagen [1] Group 2: Company Performance - The company operates six brands centered around recombinant collagen, with key brands contributing over 95% of revenue; projected revenues for 2024 are 4.54 billion and 840 million for the two main brands, with compound annual growth rates of 73.4% and 11.8% respectively from 2021 to 2024 [2] - The company is facing short-term operational pressures due to market discussions surrounding the content and testing methods of recombinant collagen, impacting brand performance, particularly for its flagship product [2] - The company is shifting from reliance on a single product to a strategy of "multiple brands, multiple categories, and multiple channels" to address challenges [2] Group 3: Product Development and Market Strategy - Plans for 2026 include launching a medical device and five skincare lines, with marketing efforts focused on core products [3] - The company aims to enhance its brand presence through collaborations and expanding its retail footprint, including increasing coverage in approximately 150,000 pharmacies nationwide [3] - The medical aesthetics sector is identified as a strategic growth area, with plans to establish a dedicated division and expand into around 2,000 medical aesthetic institutions by 2026 [3] Group 4: Financial Projections - The company is rated "outperform" with a target price of 43.6 HKD, indicating a potential upside of 22.0%; revenue projections for 2025-2027 are 5.49 billion, 5.99 billion, and 6.69 billion respectively, with expected growth rates of -0.9%, 9.1%, and 11.8% [4] - Gross margins are projected to remain stable at around 80.5% to 79.2% from 2025 to 2027, while net profit margins are expected to decline slightly [4]

Summary of Key Points Core Viewpoint - On January 14, 39 Hong Kong-listed companies conducted share buybacks, totaling 20.28 million shares and an aggregate amount of HKD 919 million [1]. Group 1: Buyback Details - Tencent Holdings repurchased 1.006 million shares for HKD 636 million, with a highest price of HKD 638.00 and a lowest price of HKD 626.00, bringing its year-to-date buyback total to HKD 57.22 billion [1]. - Xiaomi Group-W repurchased 4 million shares for HKD 151 million, with a highest price of HKD 37.80 and a lowest price of HKD 37.72, accumulating HKD 10.93 billion in buybacks year-to-date [1]. - Sunny Optical Technology repurchased 1.14 million shares for HKD 74.41 million, with a highest price of HKD 66.15 and a lowest price of HKD 64.05, totaling HKD 3.03 billion in buybacks year-to-date [1]. Group 2: Buyback Rankings - The highest buyback amount on January 14 was from Tencent Holdings at HKD 636 million, followed by Xiaomi Group-W at HKD 151 million [1]. - In terms of buyback volume, Xiaomi Group-W led with 4 million shares, followed by First Capital Holdings and Jieli Trading at 2.7 million and 2 million shares, respectively [1]. Group 3: Additional Buyback Activities - Other notable companies involved in buybacks include: - Giant Bio at 400,000 shares for HKD 1.415 million [1]. - Country Garden Services at 1 million shares for HKD 624,260 [1]. - First Capital Holdings at 2.7 million shares for HKD 561,130 [1].

| 手回集团(02621) | 1.44 万 | 5.13 万 | 42.96 万 | | | --- | --- | --- | --- | --- | | 华检医疗(01931) | 2.00 万 | 5.06 万 | 1653.40 万 | 1.020% | | 美亨实业(01897) | 10.00 万 | 4.80 万 | 162.80 万 | 0.400% | | 天福(06868) | 1.70 万 | 4.40 万 | 69.00 万 | 0.064% | | 九源基因(02566) | 3000.00 | 2.47 万 | 3.30 万 | 0.030% | | 滨海投资(02886) | 1.80 万 | 2.07 万 | 229.80 万 | 0.167% | | 同方友友(01868) | 4.60 万 | 1.83 万 | 168.40 万 | 0.080% | | 天润云(02167) | 4000.00 | 1.83 万 | 10.72 万 | 0.062% | | 乐声电子(00213) | 3.00 万 | 1.06 万 | 81.60 万 | 0.089% | | 摩比发展 ...

（原标题：巨子生物(02367.HK)连续8日回购，累计回购320.00万股） 证券时报•数据宝统计，巨子生物在港交所公告显示，1月14日以每股35.100港元至35.800港元的价格回购40.00万股，回购金额达1415.00万港元。 该股当日收盘价35.220港元，下跌1.45%，全天成交额2.70亿港元。 自1月5日以来公司已连续8日进行回购，合计回购320.00万股，累计回购金额1.11亿港元。 其间该股累计上涨2.92%。（数据宝） 巨子生物回购明细 | 日期 | 回购股数 （万股） | 回购最高价 （港元） | 回购最低价 （港元） | 回购金额 （万港元） | | --- | --- | --- | --- | --- | | 2026.01.14 | 40.00 | 35.800 | 35.100 | 1415.00 | | 2026.01.13 | 40.00 | 36.200 | 35.640 | 1433.78 | | 2026.01.12 | 40.00 | 35.500 | 34.500 | 1400.29 | | 2026.01.09 | 40.00 | 34.580 | 34.2 ...

巨子生物(02367)发布公告，于2026年1月14日，该公司斥资1415万港元回购40万股股份，每股回购价格 为35.1-35.8港元。 ...

格隆汇1月14日丨巨子生物(02367.HK)公告，1月14日耗资1415万港元回购40万股，每股回购价35.1-35.8 港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 巨子生物控股有限公司 呈交日期： 2026年1月14日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02367 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關 ...

Group 1 - The article discusses the share buybacks conducted by various companies on January 13, 2026, with Tencent Holdings (00700) having the largest buyback amount of 636 million yuan for 1.012 million shares [1][2] - Other notable companies involved in the buyback include Xiaomi Group (01810) with 4 million shares repurchased for 152 million yuan, and Sunny Optical Technology (02382) with 640,000 shares for approximately 41.79 million yuan [1][2] - The total number of shares repurchased by Tencent Holdings in the year reached 11 million, representing 1.199% of its total share capital [2] Group 2 - The buyback activities reflect a strategic move by companies to enhance shareholder value and signal confidence in their financial health [1][2] - Companies like Weigao Group (01066) and Xinli International (00732) also showed significant buyback activity, with Weigao repurchasing 27,440 shares for 1.4962 million yuan, representing 6.519% of its total share capital [2] - The data indicates a trend among companies to engage in share buybacks as a method to return capital to shareholders and potentially boost stock prices [1][2][3]

Investment Rating - The report initiates coverage with an OUTPERFORM rating for Giant Biogene, with a target price of HK$43.60, indicating a potential upside of 22.0% from the current price of HK$35.74 [1][2][7]. Core Insights - The report expresses a long-term positive outlook on the recombinant collagen sector, highlighting its advantages in safety, efficacy, and sustainability, which are seen as fundamental drivers for industry growth [4][34]. - Giant Biogene has established itself as a leader in the recombinant collagen market, with a strategic shift towards brand development in 2026 [9][30]. Financial Summary - Revenue projections for 2025, 2026, and 2027 are estimated at RMB 54.9 billion, RMB 59.9 billion, and RMB 66.9 billion, respectively, with expected growth rates of -0.9%, 9.1%, and 11.8% [7][32]. - Net profit forecasts for the same years are RMB 18.8 billion, RMB 20.0 billion, and RMB 22.1 billion, with growth rates of -9.0%, 6.6%, and 10.5% [7][32]. - The gross profit margin is expected to remain stable at approximately 80.5% in 2025, declining slightly to 79.2% by 2027 [7][32]. Brand and Product Strategy - Giant Biogene operates eight brands, with the core brands being Kefu Mei and Keli Jin, which contribute over 95% of the company's revenue [5][11][13]. - The company plans to launch a medical device and five skincare series in 2026, alongside a brand revamp for Keli Jin [6][30][31]. - The focus will be on expanding both online and offline channels, with plans to increase the number of physical stores and enhance partnerships with high-potential retailers [31][32]. Market Position and Challenges - The company faces short-term challenges due to discussions around the content and testing methods of recombinant collagen, which have impacted sales, particularly for the Kefu Mei brand [18][20][25]. - Despite these challenges, the company is adjusting its strategies, including enhancing online marketing and product offerings to stabilize and grow its market presence [25][29][30].